Zoetis stock fell 21.5% on May 7, 2026, after the animal health company reported first-quarter results that showed a significant decline across its Companion Animal business. A class action over that drop, and over what the company said before it, has a lead plaintiff deadline of July 27, 2026.
The case is City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., No. 26-cv-04401, filed in the U.S. District Court for the Southern District of New York. It covers anyone who bought or acquired Zoetis securities between January 14, 2025 and May 6, 2026. Zoetis trades on the NYSE as ZTS.
Two law firms, Kessler Topaz Meltzer & Check and Rosen Law Firm, issued reminders of the deadline in mid-July. Kessler Topaz said it did not file the complaint.
What the complaint alleges
The suit says Zoetis made false or misleading statements, and left out material facts, about its business and prospects throughout the class period. It names three problems.
First, Librela, a pain treatment for dogs. Prescription growth and use were weakening, the complaint says, after FDA safety warnings about serious neurological complications. Second, Simparica Trio, a preventative for fleas, ticks and heartworm, was losing significant market share to a lower-priced competitor. Third, the dermatology products Apoquel and Cytopoint were also ceding share to competition.
Rosen’s summary adds that the company touted growing market share, strong veterinarian adoption and accelerating sales growth across its flagship Companion Animal products. According to that account, the rival to Simparica Trio has broader indicated use in a slowing overall market, and the dermatology rival is a newly launched canine treatment.
These are allegations. Nothing in the notices reports a finding by the court.
Who can lead
A lead plaintiff is a representative who directs the case for the whole class. That is usually the investor, or small group of investors, with the largest financial interest who is also typical of the class. The lead plaintiff chooses the lawyers, subject to court approval.
Investors have three options by July 27: apply for the role, hire a lawyer of their choice, or do nothing and stay an absent class member. Their ability to share in a recovery does not depend on the choice. No class has been certified. Both firms say they work on a contingency basis, so investors owe no out-of-pocket fees.
Sources
- Zoetis Inc. (ZTS) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- ZOETIS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Zoetis …
